Aβ imaging with 18F-florbetaben in prodromal Alzheimer's disease: A prospective outcome study

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 86, Issue 4, 2015, Pages 431-436

  Ong, Kevin T ^a   Villemagne, Victor L ^a,b   Bahar Fuchs, Alex ^a,c   Lamb, Fiona ^a   Langdon, Narelle ^a   Catafau, AnaM ^d   Stephens, Andrew W ^d   Seibyl, John ^e   Dinkelborg, Ludger M ^d   Reininger, Cornelia B ^f   Putz, Barbara ^f   Rohde, Beate ^f   Masters, Colin L ^b   Rowe, Christopher C ^a  

^a AUSTIN HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^d Piramal Enterprises Limited   (India)

^e Molecular Neuroimaging   (United States)

^f BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; FLORBETABEN; 4-(N-METHYLAMINO)-4'-(2-(2-(2-FLUOROETHOXY)ETHOXY)ETHOXY)STILBENE; ANILINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; STILBENE DERIVATIVE;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; BRAIN CORTEX; BRAIN REGION; BRAIN SIZE; CALIFORNIA VERBAL LEARNING SCALE; CEREBELLUM CORTEX; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; DRUG DISTRIBUTION; DRUG RETENTION; DRUG UPTAKE; EPISODIC MEMORY; FOLLOW UP; FRONTOTEMPORAL DEMENTIA; HIPPOCAMPUS; HUMAN; IMAGING SOFTWARE; INTERMETHOD COMPARISON; MEMORY DISORDER; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PRODROMAL SYMPTOM; PROGNOSIS; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN DETERMINATION; QUANTITATIVE STUDY; STANDARDIZATION; TEMPORAL CORTEX; TISSUE DISTRIBUTION; WECHSLER MEMORY SCALE; CLINICAL TRIAL; COMPARATIVE STUDY; DIAGNOSTIC USE; FEMALE; MALE; METABOLISM; PROSPECTIVE STUDY; SCINTISCANNING;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; DISEASE PROGRESSION; FEMALE; HIPPOCAMPUS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MEMORY DISORDERS; MILD COGNITIVE IMPAIRMENT; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; STILBENES;

EID: 84925348838     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2014-308094     Document Type: Article

References (36)

1. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306-19.
2. Laforce R Jr, Rabinovici GD. Amyloid imaging in the differential diagnosis of dementia: review and potential clinical applications. Alzheimers Res Ther 2011;3:31.
3. Rowe CC, Ng S, Ackermann U, et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2007;68:1718-25.
4. Resnick SM, Sojkova J. Amyloid imaging and memory change for prediction of cognitive impairment. Alzheimers Res Ther 2011;3:3.
5. Albert MS, Dekosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:270-9.
6. Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 2010;9:1118-27.
7. Doraiswamy PM, Sperling RA, Coleman RE, et al. Amyloid-beta assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology 2012;79:1636-44.
8. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412-14.
9. Observational Study of Cognitive Outcomes for Subjects Who Have Had Prior PET Amyloid Imaging With Florbetapir F 18 (18F-AV-45). March 5, 2009 ed: Avid Radiopharmaceuticals.
10. Rowe CC, Bourgeat P, Ellis KA, et al. Predicting Alzheimer disease with beta-amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing. Ann Neurol 2013;74:905-13.
11. Zhang W, Oya S, Kung MP, et al. F-18 stilbenes as PET imaging agents for detecting beta-amyloid plaques in the brain. J Med Chem 2005;48:5980-8.
12. Rowe CC, Ackerman U, Browne W, et al. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 2008;7:129-35.
13. Barthel H, Gertz HJ, Dresel S, et al. Cerebral amyloid-beta PET with florbetaben ((18)F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol 2011;10:424-35.
14. Villemagne VL, Ong K, Mulligan RS, et al. Amyloid imaging with 18F-florbetaben in Alzheimer disease and other dementias. J Nucl Med 2011;52:1210-17.
15. Villemagne VL, Mulligan RS, Pejoska S, et al. Comparison of 11C-PiB and 18F-florbetaben for Abeta imaging in ageing and Alzheimer's disease. Eur J Nucl Med Mol Imaging 2012;39:983-9.
16. Sabbagh M, Seibyl J, Akatsu H, et al. Multicentre phase 3 trial on florbetaben for beta-amyloid brain PET in Alzheimer's disease. Alzheimer Demen 2012;8(4 Suppl):P90.
17. Jicha GA, Parisi JE, Dickson DW, et al. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol 2006;63:674-81.
18. Ong K, Villemagne VL, Lamngon N, et al. Assessment of Aβ deposition in mild cognitive impairment with 18F-florbetaben. Alzheimer Demen 2010;6:S26.
19. Mormino EC, Kluth JT, Madison CM, et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 2009;132(Pt 5):1310-23.
20. Villemagne VL, Burnham S, Bourgeat P, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 2013;12:357-67.
21. Bahar-Fuchs A, Villemagne V, Ong K, et al. Prediction of amyloid-beta pathology in amnestic mild cognitive impairment with neuropsychological tests. J Alzheimers Dis 2013;33:451-62.
22. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004;256:183-94.
23. Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment-beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004;256:240-6.
24. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 1984;34:939-44.
25. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-24.
26. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998;51:1546-54.
27. Hauw JJ, Daniel SE, Dickson D, et al. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 1994;44:2015-19.
28. Ellis KA, Bush AI, Darby D, et al. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int Psychogeriatr 2009;21:672-87.
29. Guo S, Getsios D, Hernandez L, et al. Florbetaben PET in the early diagnosis of Alzheimer's disease: a discrete event simulation to explore its potential value and key data gaps. Int J Alzheimers Dis 2012;2012:548157.
30. Nordberg A, Carter SF, Rinne J, et al. A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. Eur J Nucl Med Mol Imaging 2013;40:104-14.
31. Okello A, Koivunen J, Edison P, et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology 2009;73:754-60.
32. Wolk DA, Price JC, Saxton JA, et al. Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol 2009;65:557-68.
33. Frisoni GB, Bocchetta M, Chetelat G, et al. Imaging markers for Alzheimer disease: which vs how. Neurology 2013;81:487-500.
34. Jack CR Jr, Dickson DW, Parisi JE, et al. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology 2002;58:750-7.
35. Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9:119-28.
36. Jack CR Jr, Wiste HJ, Lesnick TG, et al. Brain beta-amyloid load approaches a plateau. Neurology 2013;80:890-6.